Homepage > Company > Media > Pharma News > 2020 > NIH to conduct studies on compound similar to remdesivir The Week

NIH to conduct studies on compound similar to remdesivir The Week

The National Institutes of Health is set to study a compound similar to remdesivir to see if it could be effective in treating COVID-19, Stat News reports.

Scientists at the NIH's National Center for Advancing Translational Sciences have determined that Gilead Sciences' GS-441524 compound "merits further exploration" and plan to "independently test the therapeutic hypothesis for GS-441524 in treating" the coronavirus, they reportedly said in a recent letter.

This compound, which has been "deemphasized" by Gilead, apparently "works in the same way as remdesivir to inhibit viruses," Stat News writes, but it has not been tested yet in humans. University of Texas MD Anderson Cancer Center researchers had been pushing for such tests, and NIH says it plans to conduct preclinical studies "quickly and make the results available to the research community for further consideration."

Researcher Victoria Yan from the Anderson Cancer Center told Stat News she's "really excited" by this decision on the part of NIH.

Aug 25, 2020,

https://sports.yahoo.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)